Onasemnogene abeparvovec-xioi (Zolgensma) — CPB 0953 | AETNA Coverage Update

Aetna modified CPB 0953 for onasemnogene abeparvovec-xioi (Zolgensma), effective September 26, 2025. Here's what changes for billing teams.

Aetna, a CVS Health company, updated its Zolgensma coverage policy under CPB 0953 Aetna system. This update reinforces precertification requirements and GCIT network site-of-care rules for HCPCS code J3399 and infusion administration codes 96365–96368. If your team bills Zolgensma for any Aetna commercial plan, this policy change has direct financial exposure — and one missed step means a claim denial.

Quick-Reference Table

Aetna Zolgensma Coverage Criteria and Medical Necessity Requirements 2025

The primary covered indication under this Aetna Zolgensma coverage policy is infantile spinal muscular atrophy, type I — ICD-10-CM code G12.0 (Werdnig-Hoffmann disease). This is the FDA-approved indication for Zolgensma, and it's the only neurological diagnosis in the covered code set.

Aetna requires you to establish medical necessity before billing J3399, the HCPCS code for onasemnogene abeparvovec-xioi injection per treatment. Medical necessity documentation must support the SMA type I diagnosis and the appropriateness of a one-time gene therapy administration. Incomplete documentation is the fastest path to a claim denial on a drug that costs over $2 million per dose.

Precertification is mandatory for all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax your prior authorization request to (888) 267-3277. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal. Do not schedule the infusion until prior authorization is confirmed in writing.

The coverage policy also ties reimbursement to site-of-care compliance. Gene and cellular therapies must be administered at an Aetna Institutes® Gene Based, Cellular and Other Innovative Therapy (GCIT®) Network facility — unless the member's specific health plan has opted out of that requirement. Confirm network status for your facility before every case. A non-GCIT site of care is a denial waiting to happen, regardless of whether the clinical criteria are met.

For Medicare billing guidelines on Zolgensma, this CPB does not apply. Aetna directs Medicare questions to its Part B step therapy criteria separately. CPB 0953 governs commercial plans only.

Aetna Zolgensma Exclusions and Non-Covered Indications

The ICD-10 code set attached to this policy includes a notable group of diagnoses that are listed but carry no coverage designation for Zolgensma: hepatitis B codes (B16.0–B16.9), hepatitis C codes (B17.10, B17.11, B17.8), chronic viral hepatitis codes (B18.0, B18.1, B18.2), unspecified viral hepatitis codes (B19.10, B19.11, B19.20, B19.21), and HIV disease (B20).

These codes appear in the policy's ICD-10 list, but they have no covered group label tied to J3399. That matters for your billing team. They are not approved indications for Zolgensma. They appear likely because Aetna screens for active hepatitis or HIV as contraindications — conditions that affect eligibility for this gene therapy due to clinical risk factors involving AAV9 vector delivery and immune response.

Do not attempt to bill J3399 against any hepatitis or HIV diagnosis code. The claim will deny, and the clinical rationale for that denial is sound. If a patient presents with SMA type I and a comorbid hepatitis or HIV diagnosis, the coverage question becomes complex. Loop in your compliance officer and the treating physician before submitting any claim in that scenario.

Coverage Indications at a Glance

Aetna Zolgensma Billing Guidelines and Action Items 2025

The effective date for this modified policy is September 26, 2025. Every action item below maps directly to a real denial risk under CPB 0953.

CPT, HCPCS, and ICD-10 Codes for Zolgensma Under CPB 0953

HCPCS Codes Covered When Selection Criteria Are Met

CPT Codes Related to Zolgensma Administration

Key ICD-10-CM Diagnosis Codes Under CPB 0953

One thing worth flagging: the policy data groups the hepatitis and HIV codes without an explicit "not covered" label in the document's code group field. They appear in the ICD-10 list with no coverage designation tied to J3399. Treat them as contraindication screening codes — not as covered or even billable indications for Zolgensma. If you're unsure how Aetna is using these codes in their claims adjudication logic for this specific member, call the payer before you bill.